

3

⁴²**ABSTRACT**

⁴³**Background:** Identifying microbial targets in irritable bowel syndrome (IBS) and other ⁴⁴disorders of gut-brain interaction (DGBI) is challenging due to the dynamic nature of ⁴⁵microbiota-metabolite-host interactions. SCFA are key microbial metabolites that modulate 46 intestinal homeostasis and may influence IBS pathophysiology. We aimed to assess microbial 47 features associated with short chain fatty acids (SCFA) and determine if features varied across ⁴⁸IBS subtypes and endophenotypes. Among 96 participants who were screened, 71 completed the ⁴⁹study. We conducted in-depth investigations of stool microbial metagenomes, stool SCFA, and 50 measurable IBS traits (stool bile acids, colonic transit, stool form) in 41 patients with IBS (IBS 51 with constipation [IBS-C] IBS with diarrhea [IBS-D]) and 17 healthy controls. We used partial 52 canonical correspondence analyses (pCCA), conditioned on transit, to quantify microbe-SCFA 53 associations across clinical groups. To explore relationships between microbially-derived SCFA 54 and IBS traits, we compared gut microbiome-encoded potential for substrate utilization across ⁵⁵groups and within a subset of participants selected by their stool characteristics as well as stool 56 microbiomes of patients with and without clinical bile acid malabsorption. ⁵⁷**Results:** Overall stool microbiome composition and individual taxa abundances differed between 58 clinical groups. Microbes-SCFA associations differed across groups and revealed key taxa ⁵⁹including *Dorea* sp. CAG:317 and *Bifidobacterium pseudocatenulatum* in IBS-D and ⁶⁰*Akkermansia muciniphila* and *Prevotella copri* in IBS-C that that may drive subtype-specific 61 microbially-mediated mechanisms. Strongest microbe-SCFA associations were observed in IBS-

- ⁶²D and several SCFA-producing species surprisingly demonstrated inverse correlations with
- 63 SCFA. Fewer bacterial taxa were associated with acetate to butyrate ratios in IBS compared to
- ⁶⁴health. In participants selected by stool form, we demonstrated differential abundances of

4

- 66 across groups. SCFA-producing taxa were reduced in IBS-D patients with BAM.
- ⁶⁷**Conclusion** Keystone taxa responsible for SCFA production differ according to IBS subtype and
- 68 traits and the IBS microbiome is characterized by reduced functional redundancy. Differences in
- ⁶⁹microbial substrate preferences are also linked to bowel functions. Focusing on taxa that drive
- 70 SCFA profiles and stool form may be a rational strategy for identifying relevant microbial targets
- 71 in IBS and other DGBI.
- ⁷²**Key words:** colonic microflora, bile acid metabolism, gut-brain interaction, functional
- 73 gastrointestinal disorder, microbiome

5

⁷⁵**INTRODUCTION**

⁷⁶Irritable bowel syndrome (IBS) is a burdensome disorder of gut-brain interaction with an 77 estimated global prevalence rate of $5{\text -}10\%$.¹ Pathophysiological mechanisms of IBS include 78 disturbances in motility or transit, altered intestinal secretion, impaired intestinal permeability, 79 immune cell reactivity, visceral hypersensitivity, and dysregulated neural signaling and/or central 80 processing.² Despite advancements in the understanding of IBS pathogenesis, diagnostic and 81 therapeutic IBS biomarkers are limited.

82 Accumulating evidence suggests that the gastrointestinal (GI) microbiome is associated 83 with risk of IBS and may also mediate many of the mechanisms that underlie symptoms 84 including altered motility,^{3, 4} barrier dysfunction,⁵ immune activation,^{6, 7} signaling along the 85 brain-gut axis, 8 and visceral sensation. 9 Characterization of microbial composition in IBS has 86 suggested decreased microbial diversity, reduced temporal stability, or changes in the relative 87 abundance of specific bacteria in patients with IBS.^{10, 11} However, these findings have not been 88 sufficiently consistent across studies to establish a clear microbial profile in IBS and gaps in our 89 understanding of the functional microbiome persist. Integrating complementary strategies in the ⁹⁰investigation of microbial metabolites will be crucial for gathering actionable insights into the 91 impact of the microbiome in IBS.

92 Atypical profiles of microbial metabolites including luminal bile acids^{12, 13} and short 93 chain fatty acids (SCFA) have been described in some patients with IBS.^{14, 15}Bile acid 94 malabsorption (BAM) is recognized as a mechanistic IBS subtype that can be assessed through several diagnostic methods including measurement of total or primary stool bile acids.¹³ Studies ⁹⁶have demonstrated BAM to be associated with physiological traits, symptoms, and quality of 97 life.¹⁶⁻¹⁹ Recently, researchers have examined microbial contributions to BAM in IBS to report

6

102 enter the colon and regulate intestinal homeostasis and physiology.²² Compared to bile acids, the 103 role of SCFA in IBS is less well understood. Studies of stool SCFA in IBS have yielded variable 104 results, which may be related to the heterogeneity of the IBS patient populations and multiple 105 pathways through which SCFA may modulate intestinal physiology. Therefore, while stool 106 SCFA are unlikely to serve as categorical IBS biomarkers, they may provide critical insights into 107 the pathophysiological mechanisms that underlie IBS symptoms or serve as a tool for identifying 108 metabolically relevant microbial targets. Studies^{15, 23} that have assessed stool SCFA in distinct 109 IBS subgroups have reported more consistent associations of stool SCFA with IBS subtypes as 110 well as correlations of stool SCFA with measurable IBS traits such as colonic transit, bowel 111 functions, and bile acid excretion.²³⁻²⁵ Despite these reports, the intercorrelation between SCFA 112 and transit time complicates the assessment of whether SCFA profiles represent the metabolic 113 capacity of the resident microbiome. It remains unclear if studying the relationships between the 114 microbiome and excreted SCFA is clinically informative. Recent work²⁶ has suggested that 115 individual or keystone taxa, rather than complex ecological communities, could drive changes in 116 SCFA output in response to dietary fiber. Therefore, strategies that isolate major microbial 117 features (or keystone taxa) that shape luminal SCFA may serve as a rational method for selecting 118 functionally relevant microbial targets in patients with IBS. To address these questions, we 119 conducted an in-depth investigation of GI microbiome composition and function, stool SCFA,

7

120 and IBS endophenotypes defined according to quantitative traits (transit, bile acids, bowel 121 functions) in adults with and without IBS.

¹²²**MATERIALS AND METHODS**

¹²³*Participant Recruitment and Study Design:* The study was approved by the Indiana University

¹²⁴Institutional Review Board and the protocol registered within ClinicalTrials.gov

¹²⁵(NCT02981888). The study was designed as an observational investigation of stool SCFA, stool

126 bile acids, colonic transit, and stool microbiota in adults with and without IBS. We enrolled

127 adults ages 18-65 years of age through the Indiana University Gastroenterology Clinics, the

128 Indiana Clinical and Translational Research Institute Research Registry, and from the local

129 community. We included individuals with IBS with diarrhea (IBS-D) or IBS with constipation

130 (IBS-C) according to Rome IV criteria²⁷ and healthy controls with no prior history of GI diseases

131 or symptoms. Detailed eligibility criteria are available in the Supplemental Methods.

¹³²*Data Collection:* Study eligibility, medications, medical history, and baseline diet using a food 133 frequency questionnaire²⁸ were assessed during a screening visit with a study physician. Over a 134 two-week period, data were collected on bowel functions using a standardized bowel pattern 135 diary including the Bristol stool form scale.²⁹ All participants submitted a 48-hour stool 136 collection collected during the last 2 days of a 4-day 100 g fat diet, consistent with clinically 137 validated methods for identifying BAM. Specimens were refrigerated during the collection 138 period, returned to the research team on ice, and stored at -80° C.

¹³⁹*Colonic Transit by Radiopaque Markers:* Participants underwent assessment of colonic transit time with a previously validated and optimized method using radiopaque markers.³⁰

9

¹⁶³(microbe-SCFA associations) across clinical groups after controlling for transit and to account 164 for the mechanistic heterogeneity that underlies clinical IBS populations.

¹⁶⁵We compared microbial taxa abundances between groups and analyzed associations of ¹⁶⁶taxa abundances with IBS endophenotypes/traits (stool SCFA, stool bile acids, and transit) for 167 the collective cohort and within groups. Associations of microbiome composition with group 168 were assessed using general linear regression models (GLM) adjusted for covariates including 169 age, sex, and BMI. Only high abundant species (relative abundance $\geq 0.1\%$) that were prevalent 170 in \geq 2 specimens within \geq 1 clinical group were considered. Partial Canonical Correspondence 171 Analysis (pCCA) conditioned on transit time was employed to quantify the relationship between 172 the microbiome and stool SCFA in all participants and within clinical groups, using the vegan 173 package in R. The significance of the model was assessed through a permutation test with 999 174 iterations. To identify bacteria whose abundances were strongly associated with the stool SCFA 175 concentrations, we focused on those bacteria scattered along the direction of specific SCFA axis 176 in the biplot, within a 60-degree angle centered around the SCFA axis in both positive and 177 negative directions. The strength of association between the bacteria and the SCFA was ranked 178 by projecting of the bacteria species scores onto each SCFA axis in the biplot. Bacteria with 179 projection scores less than 0.5 were excluded from the subsequent analysis.

180 For exploratory analyses, we analyzed multivariable associations of microbiome 181 composition with clinical BAM among individuals with IBS-D. Relative abundances were used 182 to examine the associations of gene family/pathway abundances across clinical groups. A 183 manually curated gut-metabolic analysis framework³⁷ was applied to examine KO identifiers 184 associated with carbohydrate degradation, SCFA production or metabolism, and mucin 185 degradation using GLM adjusting for covariates. As stool form³⁸ has been identified as a strong

¹⁹³**RESULTS**

¹⁹⁴*Participant Characteristics:* Among 96 volunteers who underwent screening evaluation, 71

195 completed the study, and 58 participants (Figure 1) with a mean $[\pm SD]$ age = 35.5 (\pm 13.8) years

196 and mean $[\pm SD]$ BMI = 26.2 $[\pm 7.5]$ kg/m²) were included in the final analysis after excluding

197 those who ineligible (n=16), lost to follow-up (n=9), or and/or did not provide SCFA data

 198 (n=13). Baseline clinical characteristics (Table 1) were not significantly different across groups

¹⁹⁹(all p=ns). Comparisons of quantitative traits demonstrated differences in total stool bile acids

200 and transit between IBS-D and control participants and in total stool SCFA and stool acetate)

201 between IBS and controls Table 2, Figures 2-3.

²⁰²*Stool microbiome composition differs between IBS and health and between IBS subtypes:*

203 Shotgun metagenomic sequencing of stool samples was undertaken to obtain total of 3.1 Gb of

204 sequence data after removal of contaminants with an average of 37.6 million paired-end reads

205 per sample (deposited into NCBI with accession number SUB13882354). Taxonomic

- 206 classification identified 461 taxa at species level classification. Comparisons of microbial
- 207 metagenomes based on Bray-Curtis Dissimilarity revealed significant divergence (Supplemental
- 208 Figure 1) of community distance between groups (p=0.003, R^2 =0.06) after adjusting for age,

11

230 microbiome and SCFA data, conditioned on transit time, to quantify relationships between taxa

231 abundances and stool SCFA in the overall cohort and within clinical groups. In the overall

²⁷⁶*bacterium* CAG:110, *C. leptum*, *L. asaccharolyticus*, *Ruthenibacterium lactatiformans* and

²⁷⁷*Bacteroides massiliensis* exhibited negative associations in IBS-D with only a few exceptions

14

-
- 292 functional redundancy for butyrate formation in IBS.

²⁹³*Reduced SCFA-producing microbes and bile acid malabsorption (BAM):* Stool microbial

294 metagenomes were analyzed in 22 IBS-D patients with $(n=8)$ and without $(n=14)$ clinical BAM

295 according to previously validated diagnostic cutoff values.^{12, 13} Comparisons of beta diversity

296 based on Euclidian dissimilarity of ALR transformed abundance data showed significant

297 dissimilarity ($p = 0.039$; $R^2 = 0.061$) between patients with and without BAM (Supplemental

- 298 Figure 3). Significant differences in six high abundant species were observed between groups,
- ²⁹⁹including *L. asaccharolyticus R. inulinivorans*, *L. pectinoschiza*, and *F. saccharivorans* which

15

301 known SCFA-producing capacity were negatively correlated with BAM.

³⁰²*Functional potential for carbohydrate degradation, SCFA metabolism, and mucin degradation:*

³⁰³Examination of microbial gene families and pathways yielded 949,223 total gene families within

304 the metagenome data set including 4,042 named KO terms. We applied a gut metabolic module

³⁰⁵(GMM) framework to analyze modules related to carbohydrate degradation, SCFA production or

- ³⁰⁶metabolism including bacterial cross-feeding pathways, mucin degradation, and one module
- 307 related to serine degradation based on significant species-based predictors. Abundances of KO

308 identifiers within modules for lactose degradation, $(p=0.0026)$, serine degradation (p=0.019), and

309 propionate production ($p=0.026$) were significantly enriched in IBS-C compared to controls.

310 Relative abundance of a KO identifier within a galactose degradation module was significantly

311 reduced in IBS-D ($p=0.033$) compared to controls. In the collective cohort, we applied the GMM

312 framework to analyze the relationships between metagenomically-encoded functions and stool

313 SCFA. We identified 23, 23, 15, and 16 KO identifiers from relevant GMMs that were

314 significantly associated with total SCFA, acetate, butyrate, and propionate, respectively. Within a

315 representative subset ($n=6$ controls, $n=5$ IBS-D, $n=5$ IBS-C) selected by stool form

316 characteristics, functional metagenomic analyses demonstrated that microbial genes/pathways

317 associated with SCFA production/metabolism and degradation of carbohydrates/ mucin were

318 differentially associated with clinical group (Figure 6).

³¹⁹**DISCUSSION**

320 It has been proposed that changes in intestinal SCFAs in some patients with IBS are 321 caused by shifts in microbial composition and function to drive and maintain symptoms. We ³²²hypothesized that specific features of the GI microbiome may correlate with SCFA output and

16

323 that these relationships may distinguish IBS subtypes and endophenotypes. We further ³²⁴hypothesized that functional features of the GI microbiome defined by substrate preferences and ³²⁵SCFA metabolism may be linked to bowel dysfunction. Using a dual-omics approach, our 326 findings demonstrate microbiota-SCFA relationships differ between IBS subtypes and 327 endophenotypes, and between patients with IBS and healthy controls. We elected to focus on 328 microbe-SCFA relationship due to the established biological relevance of SCFA in GI 329 physiology and to use a focused strategy for identifying the microbes involved in shaping the ³³⁰microbial metabolome. Our findings suggest that key taxa may predict IBS mechanisms and that 331 the functional repertoire of the intestinal microbiome influences bowel functions. By capturing ³³²quantifiable traits, we also gather evidence suggesting the microbiome has direct effects on 333 excreted SCFA and were able to identify microbe-SCFA relationships that are not explained by 334 transit, to potentially isolate major microbial features (or keystone taxa) that shape SCFA output. 335 While numerous studies have reported compositional changes¹¹ in IBS such as decreased 336 microbial diversity and altered abundances of individual taxa, consistent patterns are difficult to 337 pinpoint and limit our ability to draw actional insights. Recent data suggest that putative ³³⁸microbial biomarkers are related to mechanistic and host-specific features in IBS rather than the 339 overall clinical syndrome. Consistent with these prior studies, we observed differences in overall 340 microbial community composition across groups. Comparisons of taxa abundances demonstrated 341 significant changes were most common in IBS-D and predominantly characterized by higher ³⁴²abundances of several bacterial species including *Blautia* sp. CAG:257*, R. gnavus*, *Dorea* sp. ³⁴³CAG:317, and *Proteobacteria* bacterium CAG:139. *R. gnavus*, a Lachnospiraceae, has 344 previously been identified to play a pathogenic role in IBS-D through serotonin biosynthesis, 41 345 biofilm formation and increased stool bile acid excretion,²¹ production of proinflammatory

18

³⁶⁹Comparisons between IBS-D and IBS-C demonstrated differences in microbial metabolism with 370 upregulation of multiple metabolic pathways including transcripts for fructose, mannose, and 371 polyol metabolism in IBS-D. Together, our findings suggest that differences microbial ³⁷²metabolism between IBS subtypes may underlie variations in clinical symptoms or that changes 373 in microbial metabolism could play a particularly prominent role in IBS-D. These findings could 374 explain the higher prevalence of mixed- and diarrhea-predominant symptoms in post-infection 1375 IBS^{57, 58} as well as the limited evidence for efficacy of antimicrobial treatments such as rifaximin 376 in IBS-C⁵⁹ relative to IBS-D.^{60, 61}

³⁷⁷*Dorea* sp. CAG:317 and *B. pseudocatenulatum* were identified as top ranked bacteria 378 associated with acetate to butyrate ratio and acetate concentrations. Mucin degradation has been 379 described among several *Dorea* species and the genus *Dorea* belongs to the Lachnospiraceae 380 family, a major producer of SCFA, 62 Notably, Wang et al. 63 recently demonstrated that while 381 xylan supplementation following fiber deprivation alleviated gut dysbiosis through selective 382 promotion of *B. pseudocatenulatum*, these changes were found to be associated with lower ³⁸³community diversity. *Dorea* sp. CAG:317 and *B. pseudocatenulatum* may represent keystone 384 taxa linked to altered microbial metabolism or persistent impairment in community recovery ³⁸⁵among patients with IBS-D. Only two bacterial species, *A. muciniphila* and *P. copri* were 386 significantly increased in IBS-C. Although relationships between microbes and SCFA were less 387 clear in IBS-C. *P. copri* was further identified as top ranked bacteria that was positively 388 associated with propionate and negatively associated with acetate to butyrate ratio in IBS-C. 389 Previous studies have reported increased *A. muciniphila* in IBS-C to be protective against experimentally-induced colitis in mice⁶⁴ and a positive association between mucosal *P. copri* 391 abundance and abdominal pain in patients with IBS without prior history of infection.⁶⁵ Others

21

⁴³⁸intestinal metabolome or the overall metabolic potential of the colonic microbiota characterized ⁴³⁹by a decline in SCFA-producing capacity. We also assessed of functional variations in the GI ⁴⁴⁰microbiome to reveal differential abundances of KO identifiers belonging to metabolic processes 441 related to degradation of carbohydrates and serine as well as SCFA production. In a subset of ⁴⁴²participants selected by stool form characteristics, we identified changes in substrate degradation 443 potential and fermentative capacity between IBS and controls and between IBS subtypes that 444 were characterized by increased capacity for starch degradation in controls, enhancement of 445 distinct mucin-degrading functions in IBS-D vs. IBS-C, and reduced pectin degrading potential ⁴⁴⁶in IBS-C. Results suggest that abnormal stool form in IBS is influenced by microbiota-encoded 447 substrate preferences. ⁴⁴⁸Collectively, our findings indicate there are distinct changes in microbiome composition 449 may underlie clinical heterogeneity in IBS. Using a dual-omics approach, we demonstrate that

450 the gut microbiota in IBS-D is characterized by increased metabolic activity, reduced functional

⁴⁵¹redundancy, and persistently reduced diversity. Several taxa including *R. gnavus*, *Dorea* sp.

⁴⁵²CAG:317 and *B. pseudocatenulatum* are identified as the leading candidates for further study as

453 potential microbial targets in IBS-D. A few unique microbial features including *P. copri*-

⁴⁵⁴associated propionate production and *Akkermansia* expansion may play a crucial role in IBS-C.

455 Meanwhile, microbial features that are common between subtypes may offer insights into shared ⁴⁵⁶pathophysiological mechanisms involving the microbiota-gut-brain axis in IBS. Identifying the

457 major microbial features (taxa or functions) that drive metabolic output may be crucial in

458 defining rational approaches to modulate the microbiome in IBS.

459 Despite study strengths, we recognize the limitations of this work including cross-⁴⁶⁰sectional sampling, which overlooks the fluctuating nature of the microbiome. To address this,

22

⁴⁶¹we assessed relationships between microbial abundances and quantifiable IBS endophenotypes ⁴⁶²that were defined at the time of specimen collection while accounting for baseline covariates. All ⁴⁶³participants were instructed to consume a 4-day high fat diet while otherwise maintaining their ⁴⁶⁴usual diet. Previously, we examined the effect of both habitual diet and real-time intake on 465 excreted stool SCFA to find that that modest variations in macronutrient intake including 466 polysaccharides did not exert substantial effects on excreted SCFA.^{25, 77} We enrolled patients 467 with opposing IBS phenotypes from both the university clinics and the surrounding communities ⁴⁶⁸to increase our ability to detect differences between clinical cohorts and limit referral bias. We ⁴⁶⁹also acknowledge that causal microbial mechanisms cannot be determined through the current 470 work. However, we applied a dual-omics approach to investigate biologically relevant changes in 471 intestinal microbiome composition and function. Finally, we cannot discount the possibility we 472 may have missed significant taxa due to the moderate sample size and a risk for Type I errors as ⁴⁷³we did not adjust for false discovery rate in our analysis of taxonomic differences. However, our ⁴⁷⁴analytic approach was based on endpoints that were determined *a priori* and we applied a 475 conservative strategy by focusing on taxa that were associated with SCFA while accounting for 476 transit. We further limited analyses to high abundant taxa and to species that exhibited >3 -fold 477 change in abundance while focusing on the biological plausibility of our results. Findings from 478 this study should be validated in larger, longitudinal cohorts, but provide a framework that may 479 be used to define key microbial interactions and targets in IBS. 480 In conclusion, main findings from this study highlight microbiota-SCFA patterns vary 481 across clinical IBS phenotypes and endophenotypes. Our observations suggest that a paired ⁴⁸²microbe-metabolite approach may represent a viable strategy for identifying actionable microbial

⁴⁸³features in heterogenous patient populations. Prominent shifts in microbial composition are

- 484 observed in IBS-D. These changes appear to affect metabolic capacity, substrate preferences, and
- 485 metabolite profiles. In addition, altered microbial substrate uptake may impact stool form or
- 486 bowel function in IBS. These findings generate new hypotheses regarding candidate microbes
- 487 that could be pursued as actionable microbial biomarkers or metabolically influential features in
- 488 the effort to develop rational microbiota-based therapies in IBS.

⁴⁹⁰**References:**

- 559 With Colonic Transit, Fecal Bile Acid, and Food Intake in Irritable Bowel Syndrome.
- ⁵⁶⁰Clin Transl Gastroenterol 2023;14:e00541.
- 561 26. Deehan EC, Yang C, Perez-Munoz ME, et al. Precision Microbiome Modulation with
- 562 Discrete Dietary Fiber Structures Directs Short-Chain Fatty Acid Production. Cell Host
- 563 Microbe 2020;27:389-404 e6.
- ⁵⁶⁴27. Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology 2016.
- ⁵⁶⁵28. Mulligan AA, Luben RN, Bhaniani A, et al. A new tool for converting food frequency
- 566 questionnaire data into nutrient and food group values: FETA research methods and
- 567 availability. BMJ Open 2014;4:e004503.
- 568 29. Heaton KW, Radvan J, Cripps H, et al. Defecation frequency and timing, and stool form 569 in the general population: a prospective study. Gut 1992;33:818-24.
- 570 30. Sadik R, Abrahamsson H, Ung KA, Stotzer PO. Accelerated regional bowel transit and
- 571 overweight shown in idiopathic bile acid malabsorption. Am J Gastroenterol
- 572 2004;99:711-8.
- ⁵⁷³31. Park J, Kim M, Kang SG, et al. Short-chain fatty acids induce both effector and
- 574 regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-
- 575 **S6K pathway. Mucosal Immunol 2015;8:80-93.**
- 576 32. Tagliacozzi D, Mozzi AF, Casetta B, et al. Quantitative analysis of bile acids in human
- 577 plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and 578 rapid one-step method. Clin Chem Lab Med 2003;41:1633-41.
- 579 33. Vijayvargiya P, Camilleri M, Shin A, Saenger A. Methods for diagnosis of bile acid
- ⁵⁸⁰malabsorption in clinical practice. Clin Gastroenterol Hepatol 2013;11:1232-9.

- ⁵⁸³35. McMurdie PJ, Holmes S. Phyloseq: a bioconductor package for handling and analysis of
- 584 high-throughput phylogenetic sequence data. Pac Symp Biocomput 2012:235-46.
- ⁵⁸⁵36. Oksanen J, Simpson GL, Blanchet F, et al. vegan: Community Ecology Package.
- 586 **Ordination methods, diversity analysis and other functions for community and vegetation** ⁵⁸⁷ecologists. 2.6-4 ed, 2022.
- ⁵⁸⁸37. Vieira-Silva S, Falony G, Darzi Y, et al. Species-function relationships shape ecological 589 properties of the human gut microbiome. Nat Microbiol 2016;1:16088.
- ⁵⁹⁰38. Vujkovic-Cvijin I, Sklar J, Jiang L, et al. Host variables confound gut microbiota studies 591 of human disease. Nature 2020;587:448-454.
- 592 39. Saad RJ, Rao SS, Koch KL, et al. Do stool form and frequency correlate with whole-gut
- ⁵⁹³and colonic transit? Results from a multicenter study in constipated individuals and

594 healthy controls. Am J Gastroenterol 2010;105:403-11.

- ⁵⁹⁵40. Jaruvongvanich V, Patcharatrakul T, Gonlachanvit S. Prediction of Delayed Colonic
- 596 Transit Using Bristol Stool Form and Stool Frequency in Eastern Constipated Patients: A
- 597 Difference From the West. J Neurogastroenterol Motil 2017;23:561-568.
- ⁵⁹⁸41. Zhai L, Huang C, Ning Z, et al. Ruminococcus gnavus plays a pathogenic role in
- 599 diarrhea-predominant irritable bowel syndrome by increasing serotonin biosynthesis. Cell 600 Host Microbe 2023;31:33-44 e5.
- ⁶⁰¹42. Yun EJ, Yu S, Park NJ, et al. Metabolic and enzymatic elucidation of cooperative
- 602 degradation of red seaweed agarose by two human gut bacteria. Sci Rep 2021;11:13955.

- 59. Pimentel M, Chang C, Chua KS, et al. Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci 2014;59:1278-85.
- 60. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable
- bowel syndrome without constipation. N Engl J Med 2011;364:22-32.
- 61. Lembo A, Sultan S, Chang L, et al. AGA Clinical Practice Guideline on the
- Pharmacological Management of Irritable Bowel Syndrome With Diarrhea.
- 653 Gastroenterology 2022;163:137-151.
- 62. Vacca M, Celano G, Calabrese FM, et al. The Controversial Role of Human Gut
- Lachnospiraceae. Microorganisms 2020;8.
- 63. Wang Z, Bai Y, Pi Y, et al. Xylan alleviates dietary fiber deprivation-induced dysbiosis
- by selectively promoting Bifidobacterium pseudocatenulatum in pigs. Microbiome 2021;9:227.
- 64. Gobert AP, Sagrestani G, Delmas E, et al. The human intestinal microbiota of
- constipated-predominant irritable bowel syndrome patients exhibits anti-inflammatory
- 661 properties. Sci Rep 2016;6:39399.
- 65. Choo C, Mahurkar-Joshi S, Dong TS, et al. Colonic mucosal microbiota is associated
- with bowel habit subtype and abdominal pain in patients with irritable bowel syndrome.
- Am J Physiol Gastrointest Liver Physiol 2022;323:G134-G143.
- 66. Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol 2017;19:29-41.
- 667 67. Jiang L, Shang M, Yu S, et al. A high-fiber diet synergizes with Prevotella copri and 668 exacerbates rheumatoid arthritis. Cell Mol Immunol 2022;19:1414-1424.

- 670 between Bifidobacterium adolescentis and butyrate-producing anaerobes from the human
- 671 gut. Appl Environ Microbiol 2006;72:3593-9.
- 69. Duranti S, Ruiz L, Lugli GA, et al. Bifidobacterium adolescentis as a key member of the
- human gut microbiota in the production of GABA. Sci Rep 2020;10:14112.
- 70. Pichler MJ, Yamada C, Shuoker B, et al. Butyrate producing colonic Clostridiales
- metabolise human milk oligosaccharides and cross feed on mucin via conserved **pathways. Nat Commun 2020;11:3285.**
- 71. Wijdeveld M, Schrantee A, Hagemeijer A, et al. Intestinal acetate and butyrate
- availability is associated with glucose metabolism in healthy individuals. iScience 2023;26:108478.
- 72. Carco C, Young W, Gearry RB, et al. Increasing Evidence That Irritable Bowel
- 681 Syndrome and Functional Gastrointestinal Disorders Have a Microbial Pathogenesis.
- 682 Front Cell Infect Microbiol 2020;10:468.
- 73. Mulder D, Jakobi B, Shi Y, et al. Gut microbiota composition links to variation in
- functional domains across psychiatric disorders. Brain Behav Immun 2024;120:275-287.
- 74. Yu L, Chen X, Bai X, et al. Microbiota Alters and Its Correlation with Molecular
- Regulation Underlying Depression in PCOS Patients. Mol Neurobiol 2023.
- 75. Xiao L, Liu S, Wu Y, et al. The interactions between host genome and gut microbiome
- increase the risk of psychiatric disorders: Mendelian randomization and biological
- **annotation. Brain Behav Immun 2023**;113:389-400.

- 691 **Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of**
- 692 Patients with Metabolic Liver Disease. Int J Mol Sci 2023;24.
- ⁶⁹³77. Calderon G, Patel C, Camilleri M, et al. Associations of Habitual Dietary Intake With
- 694 Fecal Short-Chain Fatty Acids and Bowel Functions in Irritable Bowel Syndrome. J Clin
- 695 Gastroenterol 2022;56:234-242.

696

- 697
- 698

34

Data show mean (standard deviation	Controls $(n=17)$	IBS-C	IBS-D
$[SD]$) except where specified		$(n=15)$	$(n=26)$
Age (years)	31.7(13.6)	34.3(10.5)	38.7(15.3)
Women, n $(\frac{9}{6})$	12(71%)	13 (87%)	18 (70%)
BMI, kg/m^2	26.3(5.9)	25.3(5.2)	26.7(9.4)
White, n $(\frac{9}{6})$	9(53%)	10(67%)	23 (88%)
Baseline dietary intake*			
Energy (kcal)	1946.8 (1025.7)	2028.4 (1717.3)	1514.1 (557.4)
Total carbohydrates (g)	219.4 (155.6)	191.1 (153.7)	160.1(62.9)
Starch (g)	104.7 (54.9)	107.9 (110.9)	87.7 (46.9)
Protein (g)	100.9(47.1)	96.8(75.3)	75.1(23.4)
Fat (g)	77.6 (34.7)	99.6 (101.9)	63.8(30.3)
Fiber (g)	17.9 (20.9)	14.3(10.0)	11.6(4.1)

⁷⁰⁰**Table 1:** Clinical Characteristics of Patients with Irritable Bowel Syndrome (IBS) and Controls

⁷⁰¹*Group comparisons were conducted using the ANOVA F- and Fisher exact tests. IBS-C, IBS with*

⁷⁰²*constipation; IBS-D, IBS with diarrhea; *Diet data missing for two participants with IBS-C and*

⁷⁰³*four participants with IBS-D*

Data show median (interquartile range)	Controls	$IBS-C$	IBS-D
	$(n=17)$	$(n=15)$	$(n=26)$
Total stool bile acids $(\mu \text{mol}/48h)$ ^{**}	342 (130-640)	190 (110-449)	607 (447-1235)
Primary stool bile acids (%)	$2.1(0.8-9.1)$	$1.8(0.8-2.4)$	$3.1(0.8-12.4)$
@** Total stool SCFA (µg/mg)	$9.8(4.5-13.8)$	$11.6(7.7-20.0)$	14.3 (10.0-20.8)
Stool acetate ^{@*}	$6.3(3.3-8.5)$	$7.1(5.3-12.8)$	$9.4(5.9-14.1)$
Stool propionate	$1.7(0.8-2.4)$	$2.2(1.5-2.9)$	$2.4(1.6-4.0)$
Stool butyrate	$1.2(0.5-2.4)$	$2.2(1.0-3.7)$	$1.9(1.0-3.6)$
Acetate to butyrate ratio	$5.0(3.3-6.7)$	$3.7(2.7-4.9)$	$4.5(3.3-6.7)$
Total colonic transit time (CTT), days	$1.4(0.2-2.5)$	$1.5(1.0-2.1)$	$0.9(0.5-1.5)$
Right CTT, days	$0.6(0.3-0.6)$	$0.4(0.2-0.8)$	$0.4(0.2-0.6)$
Transverse CTT, days	$0.1(0-0.4)$	$0.3(0-0.8)$	$0.1(0-0.3)$
Left CTT, days $**$ [#]	$0.5(0.3-1.9)$	$0.5(0.2-1.1)$	$0.3(0.1-0.5)$

⁷⁰⁵**Table 2:** Quantitative Traits in Patients with Irritable Bowel Syndrome (IBS) and Controls

706 *IBS-C=IBS with constipation; IBS-D=IBS with diarrhea; SCFA=short chain fatty acids.*
707 Comparisons across groups were conducted using the Kruskal-Wallis test. For traits sho

⁷⁰⁷*Comparisons across groups were conducted using the Kruskal-Wallis test. For traits showing*

708 significant differences (*p<0.05; **p=0.05), pairwise comparisons were conducted with Dunn's
709 test, applying Bonferroni correction for multiple tests. [#]p<0.05 for Controls vs. IBS-D; ^{\$}p=0.001 *test, applying Bonferroni correction for multiple tests. # p<0.05 for Controls vs. IBS-D; \$* ⁷⁰⁹*p=0.001*

710 *for IBS-C vs. IBS-D; all other pairwise comparisons were non-significant (e.g., IBS-C vs.* 711 *controls);* $@*p<0.05$ for Controls vs. IBS. $@*p=0.05$ for Controls vs. IBS

controls); @* p <0.05 for Controls vs. IBS. @** p =0.05 for Controls vs. IBS

FIGURE LEGENDS

Figure 1: Consort Flow Diagram

- **Figure 2:** Stool Short Chain Fatty Acid Concentrations in Healthy Volunteers and Participants
- 716 with Irritable Bowel Syndrome (IBS). *Histograms are shown for total short chain fatty acids,*
- *acetate, butyrate, propionate, and acetate to butyrate ratios within clinical groups including*
- *healthy volunteers (HV), IBS with constipation (IBS-C), and IBS with diarrhea (IBS-D). Groups*
- 719 are denoted by color ($HV = red$, $IBS-C = green$, $IBS-D = blue$).
- **Figure 2:** Stool Bile Acids in Healthy Volunteers and Participants with Irritable Bowel
- Syndrome (IBS). *Histograms are shown for % primary bile acids (bile.acids) and total bile acids*
- *within clinical groups including healthy volunteers (HV), IBS with constipation (IBS-C), and IBS*
- *with diarrhea (IBS-D). Groups are denoted by color (HV = red, IBS-C = green, IBS-D = blue).*
- **Figure 4:** Bacterial Taxa with Differential Abundance of ≥3-fold Between Groups. *Data show*
- *mean percent abundances (standard deviation) of significantly different bacterial taxa with* ≥*3-*
- *fold differences in pairwise comparisons of clinical cohorts.*
- **Figures 5:** Correlations of bacterial taxa with short chain fatty acids (SCFA) based on partial
- canonical correspondence analysis. *Panels show associations between bacterial taxa and specific*
- *SCFA([a] acetate, [b] butyrate, [c] propionate, and [d] and acetate to butyrate ratio) within*
- *cohorts. The strength of the correlation is represented projections >0.5 with purple indicating*
- *negative correlations and red indicating positive correlations.*
- **Figure 6:** Variations in Microbial Substrate Utilization in Healthy Volunteers and Participants
- 733 with IBS. Figure shows significant differences in functional potential for carbohydrate
- *degradation, short chain fatty acid production or metabolism, and mucin degradation across*

- ⁷³⁵*clinical groups in representative subset selected by stool form characteristics. Groups are*
- 736 denoted by color ($HV = blue$, $IBS-C = red$, $IBS-D = gray$).

737

Histograms with Density Curves by Cohort

Histograms with Density Curves by Cohort $0.3 \sum_{0.1}^{0.2}$ Type.of.IBS HV IBS-C
IBS-D $0.0 10$ 20 30° 40 \dot{o} Acetic.to.Butyrate.ratio

Histograms with Density Curves by Cohort

Histograms with Density Curves by Cohort

Type.of.IBS

 HV
 $IBS - C$
 $IBS - D$

Histograms with Density Curves by Cohort

 H_V

*bacterial species that were significantly different in overall comparisons; ** differential increase in M. pectinilyticus abundance in IBS-C vs. controls or IBS-D <3-fold; color scheme represents relative abundance with higher values noted in darker blue

Cohort

